Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.60 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.51 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | NAMPT | P43490 | 4/20 | 0.49 |
| ▸ | TRPV1 | Q8NER1 | 4/20 | 0.48 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15573134 | 0.87 | HTT (0.80) | HTTCYP3A4MAPK14ALDH1A1NAMPT | |
| SCHEMBL15573132 | 0.85 | HTT (0.62) | HTTCYP3A4MAPK14ALDH1A1NAMPT | |
| SCHEMBL15574688 | 0.84 | HTT (0.65) | HTTCYP3A4MAPK14ALDH1A1NAMPT | |
| SCHEMBL15574779 | 0.84 | TRPV1 (0.54) | HTTCYP3A4MAPK14ALDH1A1NAMPT | |
| SCHEMBL16990678 | 0.84 | HTT (0.58) | HTTCYP3A4MAPK14ALDH1A1NAMPT | |
| SCHEMBL15575242 | 0.83 | CYP3A4 (0.62) | HTTCYP3A4MAPK14ALDH1A1NAMPT | |
| SCHEMBL16990686 | 0.82 | NAMPT (0.55) | HTTCYP3A4MAPK14ALDH1A1NAMPT | |
| SCHEMBL104548 | 0.82 | CA7 (0.63) | MAPK14NAMPTEPHX2 | |
| SCHEMBL16990726 | 0.81 | ALDH1A1 (0.61) | HTTCYP3A4MAPK14ALDH1A1NAMPT | |
| SCHEMBL16990673 | 0.81 | NAMPT (0.61) | MAPK14NAMPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150225369-A1 | DDR2 INHIBITORS FOR THE TREATMENT OF OSTEOARTHRITIS | MERCK PATENT GMBH (DE) | 2015-08-13 | — | — | US | claimed |
| US-20150225369-A1 | DDR2 INHIBITORS FOR THE TREATMENT OF OSTEOARTHRITIS | MERCK PATENT GMBH (DE) | 2015-08-13 | — | — | US | disclosed |
| US-20150225369-A1 | DDR2 INHIBITORS FOR THE TREATMENT OF OSTEOARTHRITIS | MERCK PATENT GMBH (DE) | 2015-08-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150225369-A1 | DDR2 INHIBITORS FOR THE TREATMENT OF OSTEOARTHRITIS | DDR2, DDR1, DDRGK1 | HTT 3579/4885CYP3A4 4843/4885MAPK14 455/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.